CoreAge Rx vs Superior Remedies
Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Superior Remedies head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
Superior Remedies
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 62 on our six-factor Brief Score — The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
That doesn't make Superior Remedies a bad call — it's best for readers who want a low-dose protocol designed on its own terms rather than a smaller version of a weight-loss plan, and who do not mind starting an eligibility check to learn the price. Weigh the six factors below against your own priorities before you decide.
Why CoreAge Rx leads: it's our #1 here — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| CoreAge Rx | Superior Remedies | |
|---|---|---|
| Brief Score | 94/100 (A) | 62/100 (C) |
| Semaglutide | $99/mo | Not disclosed |
| Tirzepatide | $149/mo | Not disclosed |
| Coverage | All 50 states | All 50 states (telehealth nationwide) |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.
Superior Remedies: New to the tracker on 11 August 2026, read on the provider's own site rather than taken on trust: we loaded https://superiorremedies.com/treatments/glp-1-microdose on 2026-08-11 and it publishes no price and no milligram anywhere on the page. The only figure the public site carries is a homepage headline labeled a limited-time offer, attached to the general pitch rather than to any one of its three programs. There is no earlier reading of ours to compare it against yet.
Keep comparing
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.